Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow FENNEC PHARMACEUTICALS INC.

Get SEC filing alerts via email and in your feed for FENNEC PHARMACEUTICALS INC.

FENC

FENNEC PHARMACEUTICALS INC.

About FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for reducing chemotherapy-induced ototoxicity in pediatric and adult cancer patients. Its flagship product, PEDMARK, is FDA and European approved to prevent hearing loss caused by cisplatin. The company relies on licensing, patent protection, third-party manufacturing, and targeted reimbursement strategies to serve global markets, emphasizing innovation in rare disease therapeutics.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from FENNEC PHARMACEUTICALS INC.

1
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports 72% Increase in Q1 2026 Net Product Sales

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports $9.7 Million Net Loss and Revenue Decline for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports 79% Increase in Product Sales, Continues to Face Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports Q2 2025 Financial Results with $3.15M Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports 65% Revenue Decline and $1.17 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports $47.5 Million Revenue and Reduced Losses in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
FENNEC PHARMACEUTICALS INC. Fennec Pharmaceuticals Reports Revenue Growth and Improved Financial Metrics in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments